ABE8 Base Editing of Beta-Globin Mutations for Sickle Cell Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating sickle cell disease (SCD) focus on symptom management, and there is an urgent need for genetic editing technologies to correct the underlying mutations causing the disorder.
Innovation Solution
A modified adenosine deaminase base editor (ABE8) is used to edit beta globin polynucleotides associated with SCD, targeting specific single nucleotide polymorphisms (SNPs) to alter the SNP associated with sickle cell disease, thereby correcting the genetic mutation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If current symptom management methods are used to treat sickle cell disease, then ease of operation is maintained, but manufacturing precision (genetic correction accuracy) remains insufficient
Solution Approach 1:
The base editor system is segmented into distinct functional modules: a guide RNA component for target recognition, a Cas9 nickase domain for controlled DNA cleavage, and an adenosine deaminase domain for base conversion. This segmentation allows each component to be optimized independently while working together to achieve precise genetic correction with >60-70% efficiency.
Solution Approach 2:
The Cas9 nickase acts as an intermediary that guides the adenosine deaminase to the specific target site without causing complete double-strand breaks. This intermediary mechanism enables controlled, precise editing by creating a nick that recruits the deaminase activity exactly where needed, improving correction accuracy while maintaining system manageability.
2Manufacturing precision
If base editing is used to correct genetic mutations, then manufacturing precision (editing accuracy) is improved, but loss of time (treatment duration) increases
Solution Approach 1:
The base editor system performs preliminary action by directly converting the mutant adenosine base to the correct guanine base in a single enzymatic step, rather than requiring multiple steps of DNA excision, synthesis, and ligation. This preliminary base conversion achieves >60-70% correction efficiency in one treatment cycle, significantly reducing the time required compared to traditional multi-step genetic correction methods.
Solution Approach 2:
The system replaces complex mechanical DNA repair mechanisms with a simpler chemical base conversion mechanism. Instead of requiring cellular repair pathways to be activated through multiple enzymatic steps, the adenosine deaminase directly catalyzes the chemical conversion of A to G at the target site, streamlining the correction process and reducing treatment duration while maintaining high accuracy.
3Manufacturing precision
If modified adenosine deaminase base editor is used, then manufacturing precision (correction efficiency >60-70%) is improved, but device complexity (editor structure) increases
Solution Approach 1:
The system merges the guide RNA functionality with the Cas9 nickase and adenosine deaminase into a single fused protein complex. This merging of components achieves >60-70% correction efficiency by ensuring all editing functions are delivered together to the target site, while the modular fusion structure actually simplifies delivery compared to separate component systems.
Solution Approach 2:
The base editor fusion protein exhibits multi-functionality by combining target recognition (via guide RNA binding to Cas9), DNA cleavage (via Cas9 nickase), and base conversion (via adenosine deaminase) in a single molecular complex. This universality allows one editor structure to perform all necessary editing functions, achieving high correction efficiency without requiring multiple separate molecular tools.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ABE8 achieves high efficiency (>60-70%) in correcting the SNP associated with SCD, potentially leading to improved clinical outcomes by altering the HBB polypeptide sequence, reducing the severity of the disease.
Implementation Method 1
a fusion protein comprising a polynucleotide programmable DNA binding domain and at least one base editor domain that is an adenosine deaminase variant
Data Source
AI summary
The present invention features compositions and methods for editing deleterious mutations associated with hemoglobinopathies, such as sickle cell disease (SCD). In particular embodiments, the invention provides methods for correcting mutations in a beta globin polynucleotide using modified adenosine base editors termed “ABE8” having unprecedented levels (e.g., >60-70%) of efficiency.